JPH0767544A - Feed composition and feed - Google Patents
Feed composition and feedInfo
- Publication number
- JPH0767544A JPH0767544A JP5243865A JP24386593A JPH0767544A JP H0767544 A JPH0767544 A JP H0767544A JP 5243865 A JP5243865 A JP 5243865A JP 24386593 A JP24386593 A JP 24386593A JP H0767544 A JPH0767544 A JP H0767544A
- Authority
- JP
- Japan
- Prior art keywords
- feed
- diarrhea
- tannins
- theaflavin
- infectious
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 235000018553 tannin Nutrition 0.000 claims abstract description 51
- 229920001864 tannin Polymers 0.000 claims abstract description 51
- 239000001648 tannin Substances 0.000 claims abstract description 51
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 28
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims abstract description 25
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 18
- 208000015181 infectious disease Diseases 0.000 claims abstract description 18
- 230000002458 infectious effect Effects 0.000 claims abstract description 13
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims abstract description 10
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 claims abstract description 9
- 229930013915 (+)-catechin Natural products 0.000 claims abstract description 9
- 235000007219 (+)-catechin Nutrition 0.000 claims abstract description 9
- 229930013884 (+)-gallocatechin Natural products 0.000 claims abstract description 9
- 235000007243 (+)-gallocatechin Nutrition 0.000 claims abstract description 9
- 229930013783 (-)-epicatechin Natural products 0.000 claims abstract description 9
- 235000007355 (-)-epicatechin Nutrition 0.000 claims abstract description 9
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims abstract description 9
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims abstract description 9
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 claims abstract description 7
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000014620 theaflavin Nutrition 0.000 claims abstract description 7
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 claims abstract description 7
- 229940026509 theaflavin Drugs 0.000 claims abstract description 7
- GPLOTACQBREROW-UHFFFAOYSA-N Phlegmanol A-acetat Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC1=2)C=C(O)C(=O)C1=C(O)C(O)=CC=2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GPLOTACQBREROW-UHFFFAOYSA-N 0.000 claims abstract description 6
- KMJPKUVSXFVQGZ-WQLSNUALSA-N [(2r,3r)-5,7-dihydroxy-2-[3,4,5-trihydroxy-6-oxo-1-[(2r,3r)-3,5,7-trihydroxy-3,4-dihydro-2h-chromen-2-yl]benzo[7]annulen-8-yl]-3,4-dihydro-2h-chromen-3-yl] 3,4,5-trihydroxybenzoate Chemical compound O([C@@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(=O)C(O)=C2C(O)=C(O)C=C(C2=C1)[C@H]1OC2=CC(O)=CC(O)=C2C[C@H]1O)C(=O)C1=CC(O)=C(O)C(O)=C1 KMJPKUVSXFVQGZ-WQLSNUALSA-N 0.000 claims abstract description 6
- FJYGFTHLNNSVPY-BBXLVSEPSA-N theaflavin digallate Chemical compound C1=C([C@@H]2[C@@H](CC3=C(O)C=C(O)C=C3O2)O)C=C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(=O)C2=C1C([C@H]1OC3=CC(O)=CC(O)=C3C[C@H]1O)=CC(O)=C2OC(=O)C1=CC(O)=C(O)C(O)=C1 FJYGFTHLNNSVPY-BBXLVSEPSA-N 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 claims description 8
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 244000038280 herbivores Species 0.000 claims 1
- 206010012742 Diarrhoea infectious Diseases 0.000 abstract description 32
- 208000001848 dysentery Diseases 0.000 abstract description 32
- 241001465754 Metazoa Species 0.000 abstract description 26
- 244000005700 microbiome Species 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 11
- 239000003053 toxin Substances 0.000 abstract description 10
- 231100000765 toxin Toxicity 0.000 abstract description 10
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 abstract description 8
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 abstract description 6
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 abstract description 6
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 abstract description 6
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 abstract 1
- 241000272496 Galliformes Species 0.000 abstract 1
- 244000144972 livestock Species 0.000 description 32
- 244000144977 poultry Species 0.000 description 27
- 235000013594 poultry meat Nutrition 0.000 description 27
- 235000013336 milk Nutrition 0.000 description 24
- 239000008267 milk Substances 0.000 description 24
- 210000004080 milk Anatomy 0.000 description 24
- 244000269722 Thea sinensis Species 0.000 description 23
- 235000013601 eggs Nutrition 0.000 description 22
- 241000283690 Bos taurus Species 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- 239000000427 antigen Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 15
- 239000000843 powder Substances 0.000 description 14
- 235000013616 tea Nutrition 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000037396 body weight Effects 0.000 description 10
- 210000002969 egg yolk Anatomy 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 108700012359 toxins Proteins 0.000 description 9
- 101710099478 Aminopeptidase Q Proteins 0.000 description 8
- 102000002322 Egg Proteins Human genes 0.000 description 8
- 108010000912 Egg Proteins Proteins 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 8
- 241000607142 Salmonella Species 0.000 description 8
- YMNZWKHEJQGPIA-CDJQDVQCSA-N Tavulin Chemical compound C/1=C(C)\C(O)CCC(/C)=C/C(O)C2C(=C)C(=O)OC2\1 YMNZWKHEJQGPIA-CDJQDVQCSA-N 0.000 description 8
- 235000006468 Thea sinensis Nutrition 0.000 description 8
- 235000013345 egg yolk Nutrition 0.000 description 8
- 230000002550 fecal effect Effects 0.000 description 8
- YMNZWKHEJQGPIA-UHFFFAOYSA-N tatridin-A Natural products C1=C(C)C(O)CCC(C)=CC(O)C2C(=C)C(=O)OC21 YMNZWKHEJQGPIA-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 244000309466 calf Species 0.000 description 7
- 235000013330 chicken meat Nutrition 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 241000702673 Bovine rotavirus Species 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- 235000020279 black tea Nutrition 0.000 description 6
- 235000009569 green tea Nutrition 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 108010016766 KK 3 Proteins 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 241000702670 Rotavirus Species 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 210000000991 chicken egg Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 241000589876 Campylobacter Species 0.000 description 3
- 241000193468 Clostridium perfringens Species 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 230000006651 lactation Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010048909 Boredom Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007602 hot air drying Methods 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 235000020333 oolong tea Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001522882 Clostridium perfringens A Species 0.000 description 1
- 241001327126 Clostridium perfringens C Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000205840 Escherichia coli O8 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010049040 Weight fluctuation Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- COVFEVWNJUOYRL-UHFFFAOYSA-M digallate Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C([O-])=O)O)=C1 COVFEVWNJUOYRL-UHFFFAOYSA-M 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- -1 polyphenol compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Fodder In General (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、家畜,家禽及び愛玩動
物の環境や飼料の急変、飼養失宜などの影響による非感
染性並びにウイルスもしくは細菌等の病原菌により誘発
される感染性下痢症を予防,治療する飼料組成物及びこ
れを配合した飼料に関する。より詳しくは、(+)−カ
テキン,(+)−ガロカテキン,(+)−ガロカテキン
ガレート,(−)−エピカテキン,(−)−エピカテキ
ンガレート,(−)−エピガロカテキン,(−)−エピ
ガロカテキンガレート,遊離型テアフラビン,テアフラ
ビンモノガレートA,テアフラビンモノガレートB,テ
アフラビンジガレートからなるタンニン類より選ばれる
1種又は2種以上の化合物を含有する家畜,家禽及び愛
玩動物の非感染性下痢予防,治療用飼料組成物及びこれ
を配合した飼料、又は上記記載のタンニン類に下痢症を
誘発するウイスルもしくは、細菌等の病原菌に対する特
異的抗体又はこれらの産生する毒素に対する特異的抗体
を併用する下痢予防,治療用飼料組成物及びこれを配合
した飼料に関する。FIELD OF THE INVENTION The present invention prevents non-infectious diseases caused by sudden changes in the environment and feed of livestock, poultry and pets, inadequate feeding, and infectious diarrhea induced by pathogenic bacteria such as viruses or bacteria. The present invention relates to a feed composition to be treated and a feed containing the composition. More specifically, (+)-catechin, (+)-gallocatechin, (+)-gallocatechin gallate, (-)-epicatechin, (-)-epicatechin gallate, (-)-epigallocatechin, (-) Non-infection of livestock, poultry and pet animals containing one or more compounds selected from tannins consisting of epigallocatechin gallate, free theaflavin, theaflavin monogallate A, theaflavin monogallate B and theaflavin digallate For preventing and treating sexual diarrhea, a feed containing the same and a feed containing the composition, or a virus that induces diarrhea in the tannins described above, or a specific antibody against a pathogen such as a bacterium or a specific antibody against a toxin produced by these. The present invention relates to a feed composition for preventing and treating diarrhea, which is used in combination, and a feed containing the same.
【0002】[0002]
【従来の技術】畜産経営において、家畜,家禽の下痢の
発生は深刻な問題になっている。例えば、牛に関して述
べると哺育,育成期に牛に発生する下痢等の消化器疾病
は、これが原因の死亡は言うに及ばず、体力の消耗やこ
の後の健全な内臓器官の成長に大きな影響を与えるため
に重要な問題となっている(橋本和典,肉牛ジャーナ
ル,Vol.5,No.11,38(1988))。実
際に肉用牛の育成における哺育期の下痢を主症状とする
消化器官の疾病の発生率は13.3%である(中根叔
夫,畜産の研究,Vol.33,No.1,37(19
79))。また、哺育,育成期での乳用牛の死廃率は1
1.9%に達しているが、この主な原因は下痢と肺炎で
ある(東條博之ら,畜産の研究,Vol40,No.
1,51,(1986))。さらに、成牛に関しても、
下痢が発生すると、死亡にいたらなくとも飼料効率が低
下することにより乳量,乳質,肉質の低下が認められ、
利益の損失は多大なものとなる。2. Description of the Related Art The occurrence of diarrhea of livestock and poultry has become a serious problem in livestock management. For example, when it comes to cattle, digestive diseases such as diarrhea that occur in cows during lactation and rearing have a great impact on not only death but also physical exhaustion and the growth of healthy internal organs thereafter. It has become an important issue for giving (Kazunori Hashimoto, Beef Journal, Vol. 5, No. 11, 38 (1988)). Actually, the incidence of digestive diseases with diarrhea as the main symptom during lactation in beef cattle breeding is 13.3% (Uncle Nakane, Research on Livestock, Vol.33, No.1,37 ( 19
79)). In addition, the mortality rate of dairy cows during lactation and rearing is 1
The main cause of this is diarrhea and pneumonia (Hiroyuki Tojo et al., Livestock Research, Vol 40, No. 1).
1, 51, (1986)). Furthermore, regarding adult cattle,
When diarrhea occurs, a decrease in milk yield, milk quality, and meat quality is observed due to a decrease in feed efficiency even if death does not occur.
The loss of profit will be enormous.
【0003】豚もしくは愛玩動物(ペット)についても
同様なことが言え、一般に出生直後より母子を分離して
育生することが一般的飼育形態になり、これら初生獣は
抗原性が極めて低く、また腸内細菌叢が未形成であるた
め病原菌の定着が容易となり、さらに種々のストレスに
対する抵抗性も弱く、これらが相互に作用し下痢症に陥
り 、へい死率が極めて高く、へい死を免れてもその後
の発育に多大な影響を与え、発育不良をきたすこととな
る。The same can be said for pigs or pets (pets). Generally, the mother and the baby are separated and raised immediately after birth, which is a general breeding form. Since the internal bacterial flora is not formed, colonization of pathogenic bacteria is facilitated, and resistance to various stresses is weak, and these interact with each other, resulting in diarrhea, and the mortality rate is extremely high. It has a great influence on growth and causes poor growth.
【0004】また、鶏も同様で、下痢雛は一般に発育が
悪く、体重低下,体重変動幅増大になり、その後の生産
性に悪影響を与え、ブロイラーにおいては商品化率、産
卵鶏では産卵率の低下の要因となる。さらにワクチン接
種後の抗体産生能も減少することが知られている。The same is true for chickens, and diarrhea chicks generally have poor growth, resulting in weight loss and increase in body weight fluctuation, which adversely affects productivity, and the commercialization rate in broilers and the egg production rate in laying hens. This will cause a decline. Furthermore, it is known that the antibody-producing ability after vaccination is also reduced.
【0005】ところで、これらの下痢の発生要因は、非
常に複雑でクロストリジウム パーフリンジェンス A
型,クロストリジウム パーフリンジェンス C型,サ
ルモネラ ティフィムリウム,サルモネラ タブリン,
カムピロバクター ジェジュニー,カムピロパクター
コリー,大腸菌 O−88,大腸菌 O−99,大腸菌
987P,スタフィロコッカス オウレウス,ロタウ
イルス KK−3,ロタウイルス NCDV等の病原性
細菌,下痢症ウイルスの産生する毒素又は感染による腸
内細菌叢の変化によって生じる感染性下痢だけでなく、
家畜,家禽及び愛玩動物に与えられたストレスが原因で
発生するストレス性下痢、また感染性微生物の関与して
いない原因不明の下痢といった非感染性下痢も数多く発
生している。By the way, these diarrhea-causing factors are very complicated and are caused by Clostridium perfringens A.
Type, Clostridium perfringens C type, Salmonella typhimurium, Salmonella tabulin,
Campylobacter Jewney, Campylobacter
Collagen, Escherichia coli O-88, Escherichia coli O-99, Escherichia coli 987P, Staphylococcus aureus, Rotavirus KK-3, Rotavirus NCDV and other pathogenic bacteria, toxins produced by diarrhea virus, or intestinal bacterial flora caused by infection Not only infectious diarrhea caused by changes,
Many non-infectious diarrhea such as stress-induced diarrhea caused by stress applied to livestock, poultry and pets, and unexplained diarrhea in which no infectious microorganism is involved have occurred.
【0006】これら家畜,家禽及び愛玩動物のストレス
原因は、環境の変化,栄養状態の変化,心理的な変化の
3要因であることが知られている。例えば、過密飼育,
運動不足,労力不足による畜舎の衛生管理の不備,分娩
による飼料組成の変化,離乳期における長距離の輸送な
どの様々なストレスの原因が存在している。It is known that the causes of stress in these livestock, poultry and pets are three factors: environmental changes, nutritional changes and psychological changes. For example, overcrowding,
There are various causes of stress such as lack of exercise, lack of labor for hygiene management due to lack of labor, change in feed composition due to delivery, and long-distance transportation during weaning.
【0007】さらに、出生後の初生獣は一定期間母親の
保護下で成育させるのが自然である。しかし、畜産経営
上、生産性又は経済性を向上させる目的のため、一般に
肉用牛を除いて、出生直後から母子を分離して育成する
ことが一般的飼養形態となった。母親から分離された初
生獣の大部分は生後一週間前後に哺育施設などに集めら
れ、集団的に育成される。この時、生後まもない初生獣
は抗原性が極めて低い、また腸内細菌叢が未形成である
ため、病原菌の定着が容易となり、さらに種々のストレ
スに対する抵抗性も弱く、これらが相互に作用し合い容
易に下痢性に陥ると考えられる。[0007] Furthermore, it is natural that postnatal primates are allowed to grow under the protection of their mothers for a certain period of time. However, for the purpose of improving productivity or economic efficiency in livestock management, it has been a general feeding method to separate and raise a mother and a baby immediately after birth, except for beef cattle. Most of the beasts separated from the mother are collected around a week after birth in a nursing facility and are raised collectively. At this time, the primordial animals just after birth are extremely low in antigenicity, and because the intestinal bacterial flora is not formed, colonization of pathogens is facilitated and resistance to various stresses is weak, and these interact with each other. It is considered that diarrhea easily occurs due to conflict.
【0008】従来、感染性下痢に対する予防あるいは治
療は、家畜,家禽及び愛玩動物に抗生物質を投与するこ
とが有効な手段であったが、昭和52年1月に施行され
た飼料安全法により抗生物質の種類,量が規制され、ま
た、抗生物質耐性菌の出現,安全性の面から、その有効
性は疑問視されるようになった。これに代わる方法とし
て各種天然の抗菌性物質が用いられるようになり、茶抽
出物に抗感染性微生物活性あるいはウイルス活性がある
ことは開示されている(特開平1−265023号、特
開平2−276562号)。しかしながら、茶抽出物に
単独で感染性下痢症に用いた場合あるいはこれを配合し
た飼料を用いた場合、効果が弱く、実用面で疑問視され
ている。また、特異的抗体を単独で用いる場合、実際に
は、病原性微生物は様々な種類が存在するため、これら
の有する特異性のために、下痢の予防効果は期待でき
ず、治療効果のみとなり、実用上効果的でない。Conventionally, in order to prevent or treat infectious diarrhea, it has been effective to administer an antibiotic to livestock, poultry and pet animals. However, according to the feed safety law enforced in January 1977, antibiotics were used. The types and amounts of substances have been regulated, and the effectiveness of antibiotics has been questioned due to the emergence and safety of antibiotic-resistant bacteria. As an alternative method, various natural antibacterial substances have come to be used, and it has been disclosed that tea extracts have anti-infective microbial activity or viral activity (JP-A-1-265023, JP-A-2-65023). 276562). However, when the tea extract is used alone for infectious diarrhea or when a feed containing the tea extract is used, the effect is weak, and it is doubtful in practical use. Further, when the specific antibody is used alone, in reality, since there are various types of pathogenic microorganisms, due to the specificity of these, diarrhea preventive effect cannot be expected, only therapeutic effect, Not practically effective.
【0009】一方、非感染性下痢症に対する予防,治療
法については初生獣に対し、出生後より初乳を十分量給
与する、又は、動物にストレスが生じると、結果として
感染性微生物が感染しやすい環境になる等、腸内細菌叢
に変化が生じることから感染性下痢症と同様の方法ある
いは各種生菌剤,オリゴ糖が用いられているが、これら
の方法は対処療法ににすぎない。また、生菌剤,オリゴ
糖については、効果の持続性に問題がある。また、スト
レスの予防方法としては、豚の退屈感を除くために、豚
房内に鉄製の鎖や古タイヤをつり下げて豚に自由に咬ま
せる方法や、敷きわらを毎日豚房に入れて豚に咬ませる
ことによって退屈感をまぎわらせる方法があるが、これ
は消極的予防法であり、かつ家畜,家禽及び愛玩動物の
種類も限定される。また、特公平3−17469号では
ストレス低減に家畜の馴致用組成物が開示されているが
非感染性下痢症を抑制することを期待したものではな
い。さらに、特公平3−70458号に開示されている
方法でも同様であり、かつこの方法は飼育時期、飼育環
境にも限定される。このようなことから家畜,家禽及び
愛玩動物の非感染性下痢症の発生を抑制する有効な飼料
組成物又はこれを配合した飼料が未だ見い出されていな
いのが現状である。[0009] On the other hand, regarding prevention and treatment of non-infectious diarrhea, when the primal animal is fed with sufficient amount of colostrum after birth or when stress occurs in the animal, the infectious microorganism is eventually infected. Since the intestinal microbiota changes such as in an easy environment, methods similar to those for infectious diarrhea or various probiotic agents and oligosaccharides are used, but these methods are only coping therapy. In addition, there is a problem in the sustainability of the effects of the probiotic agent and oligosaccharide. In addition, as a method of preventing stress, in order to eliminate the feeling of boredom in pigs, you can hang iron chains and old tires inside the piglet so that the pig can bite freely, or you can put the straw in the piglet every day. There is a method of circling boredom by biting a pig, but this is a passive preventive method, and the types of livestock, poultry and pet animals are also limited. Moreover, Japanese Patent Publication No. 3-17469 discloses a composition for accommodating livestock for reducing stress, but it is not expected to suppress non-infectious diarrhea. Furthermore, the method disclosed in Japanese Examined Patent Publication No. 3-70458 is the same, and this method is limited to the breeding period and breeding environment. Under such circumstances, the present situation is that no effective feed composition for suppressing the occurrence of non-infectious diarrhea in livestock, poultry and pet animals or a feed containing the same has been found yet.
【0010】[0010]
【発明が解決しようとする課題】本発明は、家畜,家禽
及び愛玩動物の非感染性下痢症及び感染性下痢症に対し
て効果のある飼料組成物及びこれを配合した飼料を供す
る事にある。DISCLOSURE OF THE INVENTION The present invention is to provide a feed composition effective for non-infectious diarrhea and infectious diarrhea of livestock, poultry and pets, and a feed containing the same. .
【0011】[0011]
【課題を解決するための手段】そこで、本発明者らは、
家畜,家禽及び愛玩動物の非感染性下痢症に対して効果
のある飼料組成物及びこれを配合した飼料について鋭意
研究した結果、(+)−カテキン,(+)−ガロカテキ
ン,(+)−ガロカテキンガレート,(−)−エピカテ
キン,(−)−エピカテキンガレート,(−)−エピガ
ロカテキン,(−)−エピガロカテキンガレート,遊離
型テアフラビン,テアフラビンモノガレートA,テアフ
ラビンモノガレートB,テアフラビンジガレート等のタ
ンニン類が非感染性下痢症に対し効果があることを見い
出し、本発明を完成させるに至った。また、さらに、こ
れらタンニン類に下痢症に対する病原性細菌もしくはウ
イルスに対する特異的抗体又はこれらの産生する毒素に
対する特異的抗体を併用するとタンニン類単独で用いる
場合と比較して感染性下痢症に対し、優れた効果を発揮
することを見い出し、本発明を完成させるに至った。Therefore, the present inventors have
As a result of diligent research on a feed composition effective for non-infectious diarrhea of livestock, poultry and pets and a feed containing the composition, (+)-catechin, (+)-gallocatechin, (+)-gallo Catechin gallate, (−)-epicatechin, (−)-epicatechin gallate, (−)-epigallocatechin, (−)-epigallocatechin gallate, free theaflavin, theaflavin monogallate A, theaflavin monogallate B, theaflavin The inventors have found that tannins such as digallate are effective against non-infectious diarrhea, and completed the present invention. Furthermore, in addition to these tannins, when in combination with a specific antibody against a pathogenic bacterium or virus against diarrhea or a specific antibody against the toxin produced by these tannins, infectious diarrhea compared to the case of using tannins alone, They have found that they exhibit excellent effects and have completed the present invention.
【0012】本発明の非感染性下痢症とは、家畜,家禽
及び愛玩動物に与えられたストレスが原因で発生するス
トレス性下痢、又は感染性微生物の関与していない原因
不明の下痢のことを指し、感染性下痢症とは下痢性病原
性細菌もしくはウイルスが原因で生じた下痢のことを指
す。また、本発明に用いられるタンニン類とは(+)−
カテキン,(+)−ガロカテキン,(+)−ガロカテキ
ンガレート,(−)−エピカテキン,(−)−エピカテ
キンガレート,(−)−エピガロカテキン,(−)−エ
ピガロカテキンガレート,遊離型テアフラビン,テアフ
ラビンモノガレートA,テアフラビンモノガレートB,
テアフラビンジガレート等のポリフェノール化合物のこ
とを指す。The non-infectious diarrhea of the present invention refers to stress diarrhea caused by stress applied to livestock, poultry and pet animals, or diarrhea of unknown cause not involving infectious microorganisms. Infectious diarrhea refers to diarrhea caused by diarrhea causing pathogenic bacteria or viruses. The tannins used in the present invention are (+)-
Catechin, (+)-gallocatechin, (+)-gallocatechin gallate, (-)-epicatechin, (-)-epicatechin gallate, (-)-epigallocatechin, (-)-epigallocatechin gallate, free form Theaflavin, theaflavin monogallate A, theaflavin monogallate B,
Refers to polyphenol compounds such as theaflavin digallate.
【0013】本発明に用いられるタンニン類は、緑茶,
紅茶,ウーロン茶等の茶の熱水抽出物の成分が好ましい
が、茶の水もしくはアルコール抽出物の酢酸エチル可溶
画分又は限外濾過膜および逆浸透膜処理により得ること
もでき、また、茶葉もしくは緑茶,ウーロン茶,紅茶等
の飲料製造時に多量に廃棄される抽出残査をこのまま、
又は粉砕等の処理を行ったものを飼料組成物として用い
ても差し支えない。さらには、柿しぶ等の他の原料起源
のものあるいは化学合成品でも差し支えない。そして、
得られたこれらのタンニン類を本発明に用いる場合は単
独で、もしくは2種以上の混合物として、さらにはタン
ニン類を含む粗抽出物でも使用できる。このようなタン
ニン類は、茶の成分として多量に含まれていることや、
既にう蝕,高脂血症,ガン予防等に効果があることか
ら、これらに関与する疾病予防のために数多くの食品に
使用されていることからもこの安全性は非常に高い。The tannins used in the present invention are green tea,
The components of hot water extract of tea such as black tea and oolong tea are preferable, but they can also be obtained by the ethyl acetate-soluble fraction of water or alcohol extract of tea or ultrafiltration membrane and reverse osmosis membrane treatment. Or a large amount of extraction residue is discarded as it is during the production of beverages such as green tea, oolong tea, and black tea,
Alternatively, it may be used as a feed composition after being subjected to treatment such as crushing. Further, it may be a material derived from other raw materials such as persimmon shibu or a chemically synthesized product. And
When the obtained tannins are used in the present invention, they can be used alone, as a mixture of two or more kinds, or even a crude extract containing tannins. Such tannins are contained in large amounts as tea ingredients,
Since it is already effective in preventing caries, hyperlipidemia, cancer, etc., it is used in many foods for the prevention of diseases related thereto, and thus this safety is very high.
【0014】本発明において非感染性下痢症を抑制する
効果を得るためには、家畜,家禽及び愛玩動物に対し、
タンニン類として通常1日当り0.5〜50mg/体重
kg、さらに好ましくは、2〜20mg/体重kgであ
る。投与量が0.5mg/体重kgより低い場合、非感
染性下痢症を抑制する効果が期待できず、また、50m
g/体重kgを越える場合、タンニン類の有する抗菌作
用のため家畜,家禽及び愛玩動物に常在する消化管微生
物に対しても影響を及ぼす。一方、感染性下痢症を抑制
する効果を期待するために、特異的抗体と併用して使用
する場合の投与量としては、タンニン類として通常、1
日当り、0.3〜25mg/体重kg、さらに好ましく
は2〜15mg/体重kgである。投与量が0.3mg
/体重kgより低い場合、感染性下痢症を抑制する効果
が期待できない。尚、タンニン類は公定タンニン分析法
により定量されるタンニンの量をもって表すことができ
る。In order to obtain the effect of suppressing non-infectious diarrhea in the present invention, it is necessary to use livestock, poultry and pet animals,
The tannins are usually 0.5 to 50 mg / kg body weight, more preferably 2 to 20 mg / kg body weight per day. If the dose is less than 0.5 mg / kg body weight, the effect of suppressing non-infectious diarrhea cannot be expected and
If the amount exceeds g / kg of body weight, the tannins have an antibacterial action, which affects the gastrointestinal microorganisms that are resident in livestock, poultry and pets. On the other hand, in order to expect the effect of suppressing infectious diarrhea, the dose when used in combination with a specific antibody is usually 1 tannin.
The daily dose is 0.3 to 25 mg / kg body weight, more preferably 2 to 15 mg / kg body weight. Dosage 0.3mg
If the weight is lower than kg, the effect of suppressing infectious diarrhea cannot be expected. The tannins can be represented by the amount of tannin quantified by the official tannin analysis method.
【0015】本発明の特異的抗体とは、家畜,家禽及び
愛玩動物の感染性微生物もしくはこれらの産生する毒素
に対して特異的に結合する抗体を言い、抗体の種類とし
ては、家畜,家禽及び愛玩動物の感染性微生物で過免疫
された産卵鶏の卵より得られる鶏卵抗体、並びに哺乳類
の乳汁より得られる乳汁抗体を言い、この抗体純度につ
いては限定しない。即ち、抗体の純品であってもよい
し、鶏卵抗体の場合は特に限定しないが、これを含む全
卵,卵黄,全卵液,卵黄液,全卵粉末,卵黄粉末もしく
は卵黄の水溶性蛋白質画分粉末であってもよい。また、
乳汁抗体の場合も特に限定しないがこれを含む全脂粉
乳,脱脂粉乳もしくは乳清蛋白質粉末であってもよい。The specific antibody of the present invention refers to an antibody that specifically binds to infectious microorganisms of livestock, poultry and pets or toxins produced by these, and the types of antibodies include livestock, poultry and poultry. It refers to chicken egg antibodies obtained from eggs of laying hens hyperimmunized with infectious microorganisms of companion animals and milk antibodies obtained from milk of mammals, and the antibody purity is not limited. That is, the antibody may be a pure product, and the chicken egg antibody is not particularly limited, but the whole egg, egg yolk, whole egg liquid, yolk liquid, whole egg powder, egg yolk powder or water-soluble protein of egg yolk containing this is not particularly limited. It may be a fraction powder. Also,
The milk antibody is not particularly limited, but may be whole milk powder, skim milk powder containing this, or whey protein powder.
【0016】家畜,家禽及び愛玩動物の感染性微生物は
特に限定されるものではないが、たとえばクロストリジ
ウム パーフリンジェンス A型,クロストリジウム
パーフリンジェンス C型,サルモネラ ティフィムリ
ウム,サルモネラ タブリン,カムピロバクター ジェ
ジュニー,カムピロパクター コリー,大腸菌 O−8
8,大腸菌 O−99,大腸菌 987P,スタフィロ
コッカス オウレウス,ロタウイルス KK−3,ロタ
ウイルス NCDV等の病原性細菌,下痢症ウイルスが
あげられる。これらなど感染症微生物又はこれらが産生
する毒素で過免疫される動物としては、該微生物に対す
る特異的抗体を産生できる動物であればよいが、本発明
の目的である家畜,家禽及び愛玩動物の感染性微生物に
対する抗体及びこの抗体組成物の応用という実用的観点
から考えると、大量の特異的抗体を産生できる産卵鶏又
は牛,ヤギ,羊等の哺乳類が特に望ましい。これらの中
でも、過免疫の作業性,抗体産生能力さらに動物飼育コ
スト等の観点から、産卵鶏を微生物もしくはこれの産生
する毒素により免疫し、この鶏卵より抗体を得る方法が
最も好ましい。The infectious microorganisms of livestock, poultry and pet animals are not particularly limited, but include, for example, Clostridium perfringens type A and Clostridium.
Perfringens type C, Salmonella typhimurium, Salmonella tabulin, Campylobacter jejuni, Campylobacter collie, E. coli O-8
8, Escherichia coli O-99, Escherichia coli 987P, Staphylococcus aureus, Rotavirus KK-3, Rotavirus NCDV and other pathogenic bacteria, and diarrhea virus. As an animal hyperimmunized with an infectious disease microorganism such as these or a toxin produced by these, any animal can be used as long as it can produce a specific antibody against the microorganism, but infection of livestock, poultry and pet animals which is the object of the present invention. From the viewpoint of practical use of antibodies against sex microorganisms and application of this antibody composition, laying hens or mammals such as cows, goats, and sheep that can produce large amounts of specific antibodies are particularly desirable. Among these, from the viewpoints of workability of hyperimmunity, antibody production ability, animal breeding cost, etc., a method of immunizing a laying hen with a microorganism or a toxin produced by the hen and obtaining an antibody from the hen's egg is most preferable.
【0017】産卵鶏を過免疫する方法としては、家畜,
家禽及び愛玩動物の感染性微生物もしくはこれの産生す
る毒素を抗原として産卵鶏に繰り返し免疫することによ
り、鶏卵中に特異的抗体を増加させるとよい。また、哺
乳類を過免疫する方法としては、牛,ヤギ,羊等の動物
に該抗原を繰り返し免疫することにより、乳汁中に特異
的抗体を増加させるとよい。As a method for hyperimmunizing a laying chicken, livestock,
It is advisable to increase specific antibody in chicken eggs by repeatedly immunizing laying hens with the infectious microorganisms of poultry and pet animals or toxins produced by them as an antigen. As a method of hyperimmunizing mammals, it is advisable to repeatedly immunize animals such as cows, goats and sheep with the antigen to increase the specific antibody in milk.
【0018】この場合用いられる抗原の調製について
は、公知の方法で行えばよい。例えば、家畜,家禽及び
愛玩動物の感染性微生物を大量培養した後、公知の方法
により弱毒化又は不活化を行い、抗原として使用すれば
良い。The antigen used in this case may be prepared by a known method. For example, a large amount of infectious microorganisms of livestock, poultry and pet animals may be cultivated, then attenuated or inactivated by a known method and used as an antigen.
【0019】抗原を産卵鶏又は哺乳類に免疫する方法と
しては、筋肉注射,皮下注射,静脈注射,腹腔内注射又
は飲水による経口免疫等、いずれの方法でも良い。As a method for immunizing laying hens or mammals with the antigen, any method such as intramuscular injection, subcutaneous injection, intravenous injection, intraperitoneal injection or oral immunization with drinking water may be used.
【0020】抗原の免疫は、鶏卵中又は乳汁中に現れる
特異的抗体価を酵素免疫測定法などの方法で調べなが
ら、該抗体価が最大値になるまで繰り返し実施される。
なお、該抗体価は、適当な間隔で産卵鶏もしくは哺乳類
に抗原を繰り返し免疫することにより、産卵期間又は初
乳分泌期間を通してある一定レベル以上の特異的抗体量
を維持することができる。The immunization with the antigen is repeated until the antibody titer reaches its maximum value while examining the specific antibody titer appearing in chicken eggs or milk by a method such as enzyme immunoassay.
The antibody titer can be maintained at a certain level or more of specific antibody throughout the spawning period or the colostrum period by repeatedly immunizing the laying hen or mammal with the antigen at appropriate intervals.
【0021】免疫される抗原の量は、被免疫動物の種
類、抗原の種類等により異なるため、適時予備試験等に
より選択する必要があるが、産卵鶏への免疫では、一般
的には、例えばウイルスの場合、ウイルス量として10
μg〜1mg/羽/回の抗原量が選択される。The amount of the antigen to be immunized varies depending on the type of animal to be immunized, the type of antigen, etc., and therefore it is necessary to select it by a timely preliminary test, etc. In the case of viruses, the virus load is 10
An antigen dose of μg to 1 mg / bird / dose is selected.
【0022】家畜,家禽及び愛玩動物の感染症微生物も
しくはこれの産生する毒素を抗原として産卵鶏もしくは
哺乳類に免疫した後、該抗原に対する特異的抗体を含有
する鶏卵又は乳汁を集め、これより本発明品に用いられ
る家畜,家禽及び愛玩動物の感染症微生物もしくはこれ
らの産生する毒素に対する特異的抗体を調製することが
できる。After immunizing a laying hen or a mammal with an infectious disease microorganism of livestock, poultry and pets or a toxin produced by the same as an antigen, chicken eggs or milk containing a specific antibody against the antigen are collected, from which the present invention is prepared. Specific antibodies to infectious microorganisms of livestock, poultry and pets used for the products or toxins produced by these can be prepared.
【0023】鶏卵を用いる場合、割卵後、全卵液もしく
は卵黄液を分離し、ホモジナイザ−等で均質化した後、
殺菌し熱風乾燥又は凍結乾燥により用いた抗原に対する
特異的抗体含有全卵粉末又は卵黄粉末を得ることができ
る。また、該卵黄液又は卵黄粉末より公知の鶏卵抗体精
製法(特開昭64−38098号、Agric.Bio
l.Chem.,Vol.54,No.10,2531
−2535(1990)等)により、用いた抗原に対す
る特異的抗体純度を高めた卵黄水溶性タンパク質粉末又
は特異的抗体の純品粉末等が調製できる。When using chicken eggs, after breaking eggs, the whole egg liquid or yolk liquid is separated and homogenized with a homogenizer or the like,
It is possible to obtain whole egg powder or egg yolk powder containing a specific antibody against the antigen that has been sterilized and dried by hot air or freeze-drying. Further, a known chicken egg antibody purification method from the egg yolk liquid or egg yolk powder (JP-A-64-38098, Agric. Bio).
l. Chem. , Vol. 54, No. 10,2531
-2535 (1990), etc., an egg yolk water-soluble protein powder or a specific antibody pure product powder having an increased purity of the specific antibody against the used antigen can be prepared.
【0024】乳汁を用いる場合、該乳汁もしくは該乳汁
中の脂質成分をクリームセパレーター等で分離した脱脂
乳を殺菌後、熱風乾燥又は凍結乾燥することにより用い
た抗原に対する特異的抗体を含有する全脂粉乳又は脱脂
粉乳が得られる。また該乳汁もしくは該脱脂乳より、公
知の方法で、用いた抗原に対する特異的抗体純度を高め
たホエータンパク質粉末又は特異的抗体の純品等も調製
できる。本発明特異的鶏卵抗体を用いる場合、感染性下
痢症の抑制効果を期待するためには、投与量として、酵
素免疫測定法でブランクに対し1.5倍以上の抗体価を
有したものを1mg/体重kg以上、さらに好ましくは
5mg/体重kgが好ましい。1mg/体重kgより少
ない投与量の場合、期待する効果が得られず好ましくな
い。When milk is used, whole milk powder containing a specific antibody against an antigen used by sterilizing the milk or skim milk obtained by separating lipid components in the milk with a cream separator or the like and then drying with hot air or freeze-drying Milk or skimmed milk powder is obtained. From the milk or the skimmed milk, a whey protein powder or a pure product of the specific antibody having an increased purity of the specific antibody against the used antigen can be prepared by a known method. When the present invention-specific chicken egg antibody is used, in order to expect an inhibitory effect on infectious diarrhea, the dose is 1 mg which has an antibody titer of 1.5 times or more that of the blank by enzyme immunoassay. / Body weight kg or more, more preferably 5 mg / body weight kg. If the dose is less than 1 mg / kg body weight, the expected effect cannot be obtained, which is not preferable.
【0025】本発明において、家畜,家禽とは、ウシ,
ブタ,ウマ,ヤギ,ヒツジ,ニワトリ,七面鳥,カモ,
ウズラ等の産業上飼育する動物のことであり、愛玩動物
とは犬,猫等の個人の趣味で飼育する動物のことであ
る。また、本発明品はすべての家畜,家禽及び愛玩動物
に用いることが出来るが、効果もしくは嗜好性の面から
草食動物はタンニン類の苦みに関係なく容易に摂取する
ことのできるため、草食動物が好ましく、特に産業上有
用である乳牛,肉牛等の牛、山羊、羊、鹿等が好まし
い。また、本発明品は組成物としてこれ単独で家畜,家
禽及び愛玩動物に投与しても良く、さらには飼料に直接
添加しても良く、この使用形態は特に限定されない。そ
して、飼料に添加する場合、この添加方法又は添加時期
等は特に限定されない。In the present invention, livestock and poultry mean cows,
Pig, horse, goat, sheep, chicken, turkey, duck,
It refers to animals that are bred for industrial purposes such as quail, and pet animals are animals that are bred for personal hobbies such as dogs and cats. Further, the product of the present invention can be used for all livestock, poultry and pet animals, but from the viewpoint of effect or palatability, herbivorous animals can be easily ingested regardless of the bitterness of tannins, so that Preferable are cows such as dairy cows and beef, and goats, sheep, and deer, which are particularly industrially useful. In addition, the product of the present invention may be administered as a composition alone to livestock, poultry and pet animals, or may be directly added to feed, and the form of use is not particularly limited. And when adding to feed, this addition method, addition timing, etc. are not particularly limited.
【0026】以下、本発明を実施例により詳細に説明す
るが、実施例のみに特に限定される物ではない。Hereinafter, the present invention will be described in detail with reference to examples, but the present invention is not limited to the examples.
【0027】[0027]
実施例1 緑茶1kgに水、約15リットルを加え攪拌し、80℃
で3時間抽出した。濾過により得られる抽出液を噴霧乾
燥し、純度25%のタンニン類を含む緑茶の熱水抽出物
350gを得た。得られたタンニン類の成分組成は、
(+)−カテキン1.2%,(+)−ガロカテキン5.
0%,(+)−ガロカテキンガレート3.9%、(−)
−エピカテキン2.3%,(−)−エピカテキンガレー
ト1.5%,(−)−エピガロカテキン5.0%及び
(−)−エピガロカテキンガレート6.1%であった。Example 1 1 kg of green tea was mixed with about 15 liters of water and stirred at 80 ° C.
It was extracted for 3 hours. The extract obtained by filtration was spray-dried to obtain 350 g of a hot water extract of green tea containing tannins having a purity of 25%. The composition of the obtained tannins is
(+)-Catechin 1.2%, (+)-gallocatechin 5.
0%, (+)-gallocatechin gallate 3.9%, (-)
-Epicatechin 2.3%, (-)-epicatechin gallate 1.5%, (-)-epigallocatechin gallate 5.0% and (-)-epigallocatechin gallate 6.1%.
【0028】実施例2 緑茶200gを85℃の熱水4リットルで30分攪拌し
ながら抽出し、茶葉を濾過により除き2.5リットルの
抽出液を得た。この液を限外濾過装置(DDS社製、膜
タイプGR−81PP、分画分子量6000)を用いて
通過液2リットルを得た。濃縮残液に水1リットルを加
え同様に操作し、通過液1.2リットルを得た。両液を
合わせ逆浸透膜(DDS社製、膜タイプHC−50)に
より濃縮し200ミリリットルとした後、凍結乾燥し、
純度29%のタンニン類を含む茶の熱水抽出物48.6
gを得た。得られたタンニン類の成分組成は、(+)−
カテキン1.4%,(+)−ガロカテキン5.8%,
(+)−ガロカテキンガレート4.5%,(−)−エピ
カテキン2.7%,(−)−エピカテキンガレート1.
8%,(−)−エピガロカテキン5.8%及び(−)−
エピガロカテキンガレート7.0%であった。Example 2 200 g of green tea was extracted with 4 liters of hot water at 85 ° C. with stirring for 30 minutes, and tea leaves were removed by filtration to obtain 2.5 liters of an extract. This liquid was passed through an ultrafiltration device (manufactured by DDS, membrane type GR-81PP, molecular weight cutoff 6000) to obtain 2 liters of a passing liquid. To the concentrated residual liquid, 1 liter of water was added and the same operation was performed to obtain 1.2 liters of the passing liquid. Both solutions were combined and concentrated with a reverse osmosis membrane (membrane type HC-50, manufactured by DDS) to 200 ml, and then freeze-dried,
Hot water extract of tea containing tannins with a purity of 29% 48.6
g was obtained. The composition of the obtained tannins is (+)-
Catechin 1.4%, (+)-gallocatechin 5.8%,
(+)-Gallocatechin gallate 4.5%, (-)-Epicatechin 2.7%, (-)-Epicatechin gallate 1.
8%, (-)-epigallocatechin 5.8% and (-)-
The epigallocatechin gallate was 7.0%.
【0029】実施例3 実施例1で得られた熱水抽出物350gに水8リットル
を加え溶解後、ヘキサン及びクロロホルムで順次分配し
た。分配後の水層に酢酸エチル10リットルを加えて激
しく攪拌,静置後、酢酸エチル層を分離し、酢酸エチル
を留去後、乾燥し、酢酸エチル可溶画分70gを得た
(タンニン類の混合物として純度74.5%)。本酢酸
エチル可溶画分の全タンニン類の含量は74.5%であ
り、各タンニン類の割合は(+)−カテキン3.5%,
(+)−ガロカテキン14.8%,(+)−ガロカテキ
ンガレート11.6%,(−)−エピカテキン7%,
(−)−エピカテキンガレート4.6%,(−)−エピ
ガロカテキン15.0%及び(−)−エピガロカテキン
ガレート18.0%であった。Example 3 To 350 g of the hot water extract obtained in Example 1, 8 liters of water was added and dissolved, and then partitioned with hexane and chloroform successively. Ethyl acetate (10 liters) was added to the aqueous layer after partitioning, and the mixture was vigorously stirred and allowed to stand, then the ethyl acetate layer was separated, and the ethyl acetate was distilled off and dried to obtain 70 g of an ethyl acetate-soluble fraction (tannins). 74.5% as a mixture of). The content of total tannins in the ethyl acetate-soluble fraction was 74.5%, the proportion of each tannin was (+)-catechin 3.5%,
(+)-Gallocatechin 14.8%, (+)-Gallocatechin gallate 11.6%, (-)-Epicatechin 7%,
The amount of (-)-epicatechin gallate was 4.6%, the amount of (-)-epigallocatechin was 15.0%, and the amount of (-)-epigallocatechin gallate was 18.0%.
【0030】実施例4 牛の感染性下痢症の原因菌として知られているサルモネ
ラ タブリン,大腸菌O−88,大腸菌 O−99及び
大腸菌 987Pをそれぞれブレインハートインフュー
ジョン培地で培養した。また、牛ロタウイルスKK−
3,牛ロタウイルスNCDVをそれぞれイーグルMEM
培地で培養したアカゲザル由来のMA104細胞を宿主
として培養した。それぞれの細菌又はウイルスを該抗原
として、産卵鶏に過免疫した。この産卵鶏が産する鶏卵
卵黄10kgより該菌に対し、特異的な鶏卵抗体45g
をそれぞれ得た。Example 4 Salmonella tabulin, Escherichia coli O-88, Escherichia coli O-99 and Escherichia coli 987P, which are known to be the causative bacteria of infectious diarrhea in cattle, were cultured in a brain heart infusion medium. In addition, bovine rotavirus KK-
3, bovine rotavirus NCDV each Eagle MEM
Rhesus monkey-derived MA104 cells cultured in a medium were used as a host. Laying hens were hyperimmunized with the respective bacteria or viruses as the antigen. From the egg yolk 10 kg produced by this laying hen, 45 g of a specific egg antibody specific to the fungus
Respectively obtained.
【0031】試験例1 30頭の子牛を10頭ずつ3群に分け、人工乳のみを与
えた群をA群、人工乳と実施例1で調製したタンニン類
を1日当り60mgとなるように添加した人工乳を与え
た群をB群、人工乳と実施例1で調製したタンニン類を
100mgとなるように添加した人工乳を与えた群をC
群として5週間飼育した。なお、人工乳および水は自由
に摂取させた。そして、非感染性下痢症を示す指標とし
て糞便スコアと腸内細菌叢を試験開始0週〜5週まで測
定した。なお、糞便スコアとは糞便の性状を数値化した
ものである。この結果をそれぞれ表1と表2に示した。Test Example 1 30 calves were divided into 3 groups with 10 calves each, the group fed only artificial milk was group A, and the artificial milk and the tannins prepared in Example 1 were 60 mg per day. The group to which the added artificial milk was added was Group B, and the group to which the artificial milk and the artificial milk to which 100 mg of the tannins prepared in Example 1 were added were given as C.
The group was raised for 5 weeks. In addition, artificial milk and water were freely taken. Then, the fecal score and the intestinal microbiota were measured from 0 to 5 weeks after the start of the test as an index showing non-infectious diarrhea. The fecal score is a numerical value of the fecal properties. The results are shown in Table 1 and Table 2, respectively.
【0032】[0032]
【表1】 [Table 1]
【0033】[0033]
【表2】 [Table 2]
【0034】表1と表2より明らなように、C群のタン
ニン類を100mg添加した人工乳で飼育した子牛は糞
便スコアが低下し、また、ウエルシュ菌,大腸菌が減少
し、ビフィズス菌,乳酸菌が増加したことにより、A群
及びB群の子牛と比較して非感染性下痢が効果良く抑制
された。また、実施例2及び実施例3で得られたタンニ
ン類を用いて同様の試験を行ったが、同様の結果が得ら
れた。さらに、紅茶,鳥龍茶由来のタンニン類を用い
て、同種の試験を行ったが、同様の結果が得られた。As is clear from Tables 1 and 2, calves bred with artificial milk containing 100 mg of tannins of group C had a reduced fecal score and decreased C. perfringens and Escherichia coli, and Bifidobacterium. The increase in lactic acid bacteria effectively suppressed non-infectious diarrhea as compared with calves in groups A and B. The same test was conducted using the tannins obtained in Examples 2 and 3, but the same result was obtained. Further, the same type of test was conducted using tannins derived from black tea and choiryu tea, but similar results were obtained.
【0035】試験例2 15頭の分娩直後の成牛を5頭ずつ3群に分け、表3に
示した基本飼料を与えた群をD群、表3に示した基本飼
料1kgに実施例1で調製したタンニン類を10g添加
した飼料を与えた群をE群、表5に示した基本飼料に実
施例1で調製したタンニン類を15g添加した飼料を与
えた群をF群とし5週間飼育した。なお、飼料および水
は自由に摂取させた。そして、非感染性下痢症を示す指
標として試験例1と同様に糞便スコアと腸内細菌叢を試
験開始0週〜5週まで測定した。この結果をそれぞれ表
4と表5に示した。Test Example 2 15 adult cattle immediately after calving were divided into 3 groups of 5 cows each, the group fed the basic feed shown in Table 3 was group D, and 1 kg of the basic feed shown in Table 3 was used in Example 1. The group fed with the feed containing 10 g of the tannins prepared in 1. was designated as group E, and the group fed with the feed containing 15 g of the tannins prepared in Example 1 added to the basic diet shown in Table 5 was designated as group F for 5 weeks. did. The feed and water were taken freely. Then, as an index showing non-infectious diarrhea, in the same manner as in Test Example 1, the fecal score and the intestinal microbiota were measured from 0 to 5 weeks after the start of the test. The results are shown in Table 4 and Table 5, respectively.
【0036】[0036]
【表3】 [Table 3]
【0037】[0037]
【表4】 [Table 4]
【0038】[0038]
【表5】 [Table 5]
【0039】表4と表5より明らなように、表3に示し
た基本飼料1kgにタンニン類を15g添加したF群の
成牛はD群及びE群で飼育した成牛と比較して、糞便ス
コアは低下し、また、ウエルシュ菌,大腸菌群が減少
し、ビフィズス菌,乳酸菌が増加し、分娩によって生じ
たストレス性(非感染性)の下痢が効果的に抑制され
た。また、実施例2及び実施例3で得られたタンニン類
を用いて同様の試験を行ったが、同様の結果が得られ
た。さらに、紅茶,鳥龍茶由来のタンニン類を用いた同
種の試験を行なったが、同様の結果が得られた。As can be seen from Tables 4 and 5, the adult cows of group F in which 15 g of tannins were added to 1 kg of the basic feed shown in table 3 were compared with adult cows raised in groups D and E. , Fecal score decreased, C. perfringens and coliforms decreased, bifidobacteria and lactic acid bacteria increased, and stress-induced (non-infectious) diarrhea caused by delivery was effectively suppressed. The same test was conducted using the tannins obtained in Examples 2 and 3, but the same result was obtained. Furthermore, the same type of test was conducted using tannins derived from black tea and Toryu tea, and similar results were obtained.
【0040】試験例3 サルモネラ タブリンで感染させた30頭の子牛を10
頭ずつ3群に分け、人工乳のみを与えた群をG群(無添
加群)、人工乳に実施例1で調製したタンニン類を1日
当り30mgとなるように添加した人工乳を与えた群を
H群(タンニン類のみ添加群)、また人工乳に実施例1
で調製したタンニン類を30mg及び実施例4で調製し
た特異的鶏卵抗体を1日当り400mgとなるように添
加した人工乳を与えた群をI群(タンニン類と特異的鶏
卵抗体添加群)とし5週間飼育した。そして、下痢症を
示す指標として糞便スコアと糞便中のサルモネラ タブ
リンの菌数を試験開始0週〜5週まで求めた。この結果
をそれぞれ表6と表7に示した。Test Example 3 10 calves infected with Salmonella tabulin were treated with 10 calves.
The heads were divided into 3 groups, the group to which only artificial milk was given was a group G (no addition group), and the group to which artificial milk to which the tannins prepared in Example 1 were added at 30 mg per day was given to the artificial milk group. Example 1 was added to H group (group containing only tannins) and artificial milk.
The group to which 30 mg of the tannins prepared in 1 and the specific egg egg antibody prepared in Example 4 was added so as to be 400 mg per day was designated as a group I (tannins and specific egg egg antibody added group) 5 Raised for a week. Then, the fecal score and the number of salmonella tabulin in the feces as indexes showing diarrhea were determined from 0 to 5 weeks after the start of the test. The results are shown in Table 6 and Table 7, respectively.
【0041】[0041]
【表6】 [Table 6]
【0042】[0042]
【表7】 [Table 7]
【0043】表6と表7から、I群はG群及びH群の子
牛と比較して糞便スコアが低下し、糞便中のサルモネラ
タブリンの菌数が減少したことより感染性の下痢が効
果的に抑制されることがわかった。また、実施例2及び
実施例3で得られたタンニン類を用いて同様の試験を行
ったが、同様の結果が得られた。さらに、紅茶,鳥龍茶
由来のタンニン類を用いて同様の試験を行ったが、同様
の効果が得られた。また、大腸菌0−88,大腸菌0−
99,大腸菌987P,牛ロタウイルスKK−3及び牛
ロタウイルスNCDVで同様の感染症下痢の試験を行っ
たが同様の結果が得られた。From Tables 6 and 7, the fecal score of group I was lower than that of the calves of group G and group H, and the number of salmonella tabulin in feces was decreased, so that infectious diarrhea was effective. It turned out that it was suppressed. The same test was conducted using the tannins obtained in Examples 2 and 3, but the same result was obtained. Furthermore, the same test was conducted using tannins derived from black tea and choiryu tea, but similar effects were obtained. In addition, E. coli 0-88, E. coli 0-
99, Escherichia coli 987P, bovine rotavirus KK-3 and bovine rotavirus NCDV were tested for similar infectious diarrhea, but similar results were obtained.
【0044】試験例4 サルモネラ タブリンで感染させた15頭の成牛を5頭
ずつ3群に分け、表3に示した基本飼料を与えた群をJ
群(無添加群)、基本飼料1kgに実施例1で調製した
タンニン類を7.5g添加した群をK群(タンニン類の
み添加群)、基本飼料1kgに実施例1で調製したタン
ニン類を7.5gと実施例4で調製した特異的鶏卵抗体
を6g添加した群を飼料を与えた群をL群(タンニン類
と特異的鶏卵抗体添加群)として5週間飼育した。な
お、飼料および水は自由に摂取させた。そして、試験例
3と同様に下痢症を示す指標として糞便スコアと糞便中
のサルモネラ タブリンの菌数を試験開始0週〜5週ま
で求めた。この結果をそれぞれ表8と表9に示した。Test Example 4 15 adult cattle infected with Salmonella tabulin were divided into 3 groups of 5 cows each, and the group fed with the basic diet shown in Table 3 was designated as J.
Group (non-addition group), group in which 7.5 g of tannins prepared in Example 1 was added to 1 kg of basic feed, Group K (group in which only tannins were added), tannins prepared in Example 1 in 1 kg of basic feed A group to which 7.5 g and 6 g of the specific egg egg antibody prepared in Example 4 were added was fed as a group L (tannins and specific egg egg antibody added group) for 5 weeks. The feed and water were taken freely. Then, as in Test Example 3, the stool score and the number of salmonella tabulin in the stool were determined from 0 to 5 weeks after the start of the test as an index showing diarrhea. The results are shown in Table 8 and Table 9, respectively.
【0045】[0045]
【表8】 [Table 8]
【0046】[0046]
【表9】 [Table 9]
【0047】表8と表9より、L群の成牛はJ群及びK
群の成牛と比較して感染性下痢が効果良く抑制された。
また、実施例2及び実施例3で得られたタンニン類を用
いて同様の試験を行ったが、同様の結果が得られた。さ
らに、紅茶、鳥龍茶由来のタンニン類を用いて同種の試
験を行なったが、同様の結果が得られた。また大腸菌0
−88,大腸菌0−99,大腸菌987P,牛ロタウイ
ルスKK−3及び牛ロタウイルスNCDVを用いて同様
の試験を行ったが、同様の結果が得られた。From Tables 8 and 9, the adult cows of group L are J group and K group.
Infectious diarrhea was effectively suppressed compared with the adult cows in the herd.
The same test was conducted using the tannins obtained in Examples 2 and 3, but the same result was obtained. Further, the same type of test was conducted using tannins derived from black tea and choiryu tea, and similar results were obtained. Also E. coli 0
Similar tests were performed using -88, E. coli 0-99, E. coli 987P, bovine rotavirus KK-3 and bovine rotavirus NCDV, but similar results were obtained.
【0048】[0048]
【発明の効果】以上説明したように、本発明品は、家
畜,家禽及び愛玩動物の非感染性下痢症および感染性下
痢症に多大な効果があり、本発明品に含有しているタン
ニン類は消臭効果も有しているので家畜,家禽及び愛玩
動物の排泄する糞,尿の消臭効果も有し、畜産業界及び
ペット業界に貢献するところは多大である。INDUSTRIAL APPLICABILITY As described above, the product of the present invention has a great effect on non-infectious diarrhea and infectious diarrhea of livestock, poultry and pet animals, and the tannins contained in the product of the present invention Also has a deodorizing effect, it also has a deodorizing effect on feces and urine excreted by livestock, poultry and pets, and it greatly contributes to the livestock industry and pet industry.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 赤地 重光 三重県四日市市赤堀新町9番5号 太陽化 学株式会社内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Shigemitsu Akachi 9-5 Akahori Shinmachi, Yokkaichi-shi, Mie Taiyo Kagaku Co., Ltd.
Claims (3)
ン,(+)−ガロカテキンガレート,(−)−エピカテ
キン,(−)−エピカテキンガレート,(−)−エピガ
ロカテキン,(−)−エピガロカテキンガレート,遊離
型テアフラビン,テアフラビンモノガレートA,テアフ
ラビンモノガレートB,テアフラビンジガレートからな
るタンニン類より選ばれる1種又は2種以上の化合物を
含有することを特徴とする非感染性下痢予防,治療用飼
料組成物及びこれを配合した飼料。1. (+)-Catechin, (+)-gallocatechin, (+)-gallocatechin gallate, (-)-epicatechin, (-)-epicatechin gallate, (-)-epigallocatechin, (-) ) -Epigallocatechin gallate, free theaflavin, theaflavin monogallate A, theaflavin monogallate B, non-infectious characterized by containing one or more compounds selected from tannins consisting of theaflavin digallate A feed composition for preventing and treating diarrhea and a feed containing the same.
ン,(+)−ガロカテキンガレート,(−)−エピカテ
キン,(−)−エピカテキンガレート,(−)−エピガ
ロカテキン,(−)−エピガロカテキンガレート,遊離
型テアフラビン,テアフラビンモノガレートA,テアフ
ラビンモノガレートB,テアフラビンジガレートより選
ばれる1種又は2種以上の化合物に、特異的抗体を併用
することを特徴とする下痢症の予防,治療用飼料組成物
及びこれを配合した飼料。2. (+)-Catechin, (+)-gallocatechin, (+)-gallocatechin gallate, (-)-epicatechin, (-)-epicatechin gallate, (-)-epigallocatechin, (-) ) -Epigallocatechin gallate, free theaflavin, theaflavin monogallate A, theaflavin monogallate B, theaflavin digallate, or one or more compounds selected from diarrhea characterized by using a specific antibody in combination A preventive and therapeutic feed composition and a feed containing the same.
食動物用であることを特徴とする請求項1及び2記載の
飼料組成物及びこれを配合した飼料。3. The feed composition according to claim 1, wherein the feed composition and the feed containing the feed composition are for herbivores, and the feed containing the feed composition.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5243865A JPH0767544A (en) | 1993-09-03 | 1993-09-03 | Feed composition and feed |
AU69839/94A AU6983994A (en) | 1993-06-30 | 1994-06-27 | Feed additive of tea origin and animal feed containing the same |
PCT/JP1994/001037 WO1995001104A1 (en) | 1993-06-30 | 1994-06-27 | Feed additive of tea origin and animal feed containing the same |
US08/997,798 US6068862A (en) | 1993-06-30 | 1997-12-24 | Tea-derived feed additive and animal feed containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5243865A JPH0767544A (en) | 1993-09-03 | 1993-09-03 | Feed composition and feed |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0767544A true JPH0767544A (en) | 1995-03-14 |
Family
ID=17110131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5243865A Pending JPH0767544A (en) | 1993-06-30 | 1993-09-03 | Feed composition and feed |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0767544A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09291039A (en) * | 1995-12-26 | 1997-11-11 | Suntory Ltd | Antiobestic medicine comprising procyanidin as active ingredient |
WO1999023892A1 (en) * | 1997-11-11 | 1999-05-20 | Inaba Shokuhin Co., Ltd. | Cat food |
JP2002537861A (en) * | 1999-03-10 | 2002-11-12 | マーズ ユー ケー リミテッド | Pet food products containing coconut endosperm fiber |
JP2002360185A (en) * | 2001-06-11 | 2002-12-17 | Hokkai Can Co Ltd | Feed substance |
JP2007117029A (en) * | 2005-10-31 | 2007-05-17 | Nippon Beet Sugar Mfg Co Ltd | Composition for improving iron excess condition inside livestock body |
JP2007518741A (en) * | 2004-01-16 | 2007-07-12 | ザ・アイムス・カンパニー | Liquid supplement composition comprising one or more drugs |
WO2023148882A1 (en) * | 2022-02-03 | 2023-08-10 | 味の素株式会社 | Agent for improving livestock intestinal bacterial flora |
-
1993
- 1993-09-03 JP JP5243865A patent/JPH0767544A/en active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09291039A (en) * | 1995-12-26 | 1997-11-11 | Suntory Ltd | Antiobestic medicine comprising procyanidin as active ingredient |
WO1999023892A1 (en) * | 1997-11-11 | 1999-05-20 | Inaba Shokuhin Co., Ltd. | Cat food |
JP2002537861A (en) * | 1999-03-10 | 2002-11-12 | マーズ ユー ケー リミテッド | Pet food products containing coconut endosperm fiber |
JP4970656B2 (en) * | 1999-03-10 | 2012-07-11 | マーズ ユー ケー リミテッド | Pet food products containing coconut endosperm fiber |
JP2002360185A (en) * | 2001-06-11 | 2002-12-17 | Hokkai Can Co Ltd | Feed substance |
JP2007518741A (en) * | 2004-01-16 | 2007-07-12 | ザ・アイムス・カンパニー | Liquid supplement composition comprising one or more drugs |
JP2007117029A (en) * | 2005-10-31 | 2007-05-17 | Nippon Beet Sugar Mfg Co Ltd | Composition for improving iron excess condition inside livestock body |
WO2023148882A1 (en) * | 2022-02-03 | 2023-08-10 | 味の素株式会社 | Agent for improving livestock intestinal bacterial flora |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6068862A (en) | Tea-derived feed additive and animal feed containing the same | |
AU721811B2 (en) | Animal feed | |
CA2886244C (en) | Probiotic and prebiotic compositions | |
AU2005211140B2 (en) | Use of live bacteria for growth promotion in animals | |
CN112996808A (en) | Compositions and methods for treating acute diarrhea and intestinal infections in animals | |
JP4127864B2 (en) | Gram-negative bacterial growth inhibitor | |
Iegorov et al. | Probiotic feed additives in fattening of agricultural animals | |
JPH0767544A (en) | Feed composition and feed | |
JP4073922B2 (en) | Feed composition containing bifidobacteria growth promoting component and method of use | |
EP0914831B1 (en) | Biological product for preventive or therapeutic oral administration against canine parvovirosis | |
JP5584124B2 (en) | Anti-coccidial composition | |
Özpinar et al. | Dose-dependent effects of specific egg-yolk antibodies on diarrhea of newborn calves | |
Thakur et al. | Strategies to minimize the impact of antibiotic resistance in livestock production system | |
WO1995001104A1 (en) | Feed additive of tea origin and animal feed containing the same | |
JP2001309753A (en) | Dog food for prophylaxis and therapy of infectious disease peculiar to dog | |
JPH10262571A (en) | Feed for animal | |
RU2504386C1 (en) | Preparation for prevention of diarrhoea in newborn calves | |
JP2583382B2 (en) | Livestock and poultry feed containing purslane | |
WO1996010420A1 (en) | Composition and treatment for hyperimmunization with non heat-killed bacteria | |
JPH10165109A (en) | Feed composition and feed | |
JPH0748274A (en) | Production of preventing and therapeutic feed for pathogenic microbism in farming fishery | |
JPH10179040A (en) | Feed composition and feed | |
KR20030017448A (en) | Method-breeding of environmental friendly hen using non antibiotic treatment | |
Patil | Eggshell quality: 3 solutions for older laying birds | |
Spătariu et al. | Implementation of a pharmacologic protocol for testing bovine colostrum nutraceutical products in Broilers |